Manav Korpal

4.8k total citations · 3 hit papers
23 papers, 3.3k citations indexed

About

Manav Korpal is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Manav Korpal has authored 23 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 10 papers in Pulmonary and Respiratory Medicine and 8 papers in Oncology. Recurrent topics in Manav Korpal's work include Advanced Breast Cancer Therapies (5 papers), MicroRNA in disease regulation (4 papers) and Cancer Treatment and Pharmacology (4 papers). Manav Korpal is often cited by papers focused on Advanced Breast Cancer Therapies (5 papers), MicroRNA in disease regulation (4 papers) and Cancer Treatment and Pharmacology (4 papers). Manav Korpal collaborates with scholars based in United States, United Kingdom and Italy. Manav Korpal's co-authors include Yibin Kang, Guohong Hu, Joshua M. Korn, Adrian L. Harris, Jiannis Ragoussis, Dorothy A. Lerit, Hani Goodarzi, Toni Ibrahim, Toni Celià-Terrassa and Jun Yan and has published in prestigious journals such as Journal of Biological Chemistry, Nature Medicine and Journal of Clinical Oncology.

In The Last Decade

Manav Korpal

21 papers receiving 3.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The miR-200 Family Inhibits Epithelial-Mesenchymal Transition and Cancer Cell Migration by Direct Targeting of E-cadherin Transcriptional Repressors ZEB1 and ZEB2

2008 1.4k citations Manav Korpal, Guohong Hu et al. Journal of Biological Chemistry profile →
Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization

2011 508 citations Manav Korpal, Brian Ell et al. Nature Medicine profile →
An F876L Mutation in Androgen Receptor Confers Genetic and Phenotypic Resistance to MDV3100 (Enzalutamide)

2013 425 citations Manav Korpal, Joshua M. Korn et al. Cancer Discovery profile →

Peers

Manav Korpal

ONCOL

PRM

GENET

Madhu Kumar India

François Lamoureux France

Alessia Ciarrocchi Italy

Sílvia Menéndez United States

Arnulfo Mendoza United States

Carrie A. Adelman United States

Kazunori Tsukuda Japan

Eijiro Nakamura Japan

Joseph Abecassis France

Nathalie Cervera France

Madhu Kumar India

Manav Korpal

2.3k ×1.0

1.1k ×0.7

828 ×0.9

ONCOL

458 ×0.7

PRM

104 ×0.4

GENET

Citations per year, relative to Manav Korpal Manav Korpal (= 1×) peers Madhu Kumar

Countries citing papers authored by Manav Korpal

Since Specialization

Citations

This map shows the geographic impact of Manav Korpal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Manav Korpal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Manav Korpal more than expected).

Fields of papers citing papers by Manav Korpal

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Manav Korpal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Manav Korpal. The network helps show where Manav Korpal may publish in the future.

Co-authorship network of co-authors of Manav Korpal

This figure shows the co-authorship network connecting the top 25 collaborators of Manav Korpal. A scholar is included among the top collaborators of Manav Korpal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Manav Korpal. Manav Korpal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wang, Haizhen, Yu Zhou, Chen Chu, et al.. (2023). Generating a Murine PTEN Null Cell Line to Discover the Key Role of p110β-PAK1 in Castration-Resistant Prostate Cancer Invasion. Molecular Cancer Research. 21(12). 1317–1328. 1 indexed citations

Parker, Mackenzie J., Hyelee Lee, Shihua Yao, et al.. (2023). Identification of 2-Sulfonyl/Sulfonamide Pyrimidines as Covalent Inhibitors of WRN Using a Multiplexed High-Throughput Screening Assay. Biochemistry. 62(14). 2147–2160. 16 indexed citations

Irwin, Sean, Craig Karr, Craig Furman, et al.. (2022). Biochemical and structural basis for the pharmacological inhibition of nuclear hormone receptor PPARγ by inverse agonists. Journal of Biological Chemistry. 298(11). 102539–102539. 7 indexed citations

Johnston, Stephen, Timothy Pluard, Erika Hamilton, et al.. (2022). Abstract P1-17-03: H3B-6545 in combination with palbociclib in women with metastatic estrogen receptor-positive (ER+), human epidermal growth factor receptor 2 (HER2)-negative breast cancer, phase 1b study. Cancer Research. 82(4_Supplement). P1–17. 2 indexed citations

Johnston, Stephen, Timothy Pluard, Judy S. Wang, et al.. (2021). Phase 1b study of H3B-6545 in combination with palbociclib in women with metastatic estrogen receptor–positive (ER+), human epidermal growth factor receptor 2 (HER2)-negative breast cancer.. Journal of Clinical Oncology. 39(15_suppl). e13025–e13025. 9 indexed citations

Hamilton, Erika, Judy S. Wang, Timothy Pluard, et al.. (2021). Phase I/II study of H3B-6545, a novel selective estrogen receptor covalent antagonist (SERCA), in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer.. Journal of Clinical Oncology. 39(15_suppl). 1018–1018. 31 indexed citations

Furman, Craig, Ming‐Hong Hao, Sudeep Prajapati, et al.. (2019). Estrogen Receptor Covalent Antagonists: The Best Is Yet to Come. Cancer Research. 79(8). 1740–1745. 26 indexed citations

Rioux, Nathalie, Sherri Smith, Manav Korpal, et al.. (2018). Nonclinical pharmacokinetics and in vitro metabolism of H3B-6545, a novel selective ERα covalent antagonist (SERCA). Cancer Chemotherapy and Pharmacology. 83(1). 151–160. 14 indexed citations

Thomas, Michaël, Alyssa Moriarty, Maria Cristina Guerra, et al.. (2017). Abstract P3-04-26: Establishment and characterization of ST941/C; an ESR1-mutant ER+ breast cancer cell line and xenograft from a patient with acquired resistance to endocrine therapy. Cancer Research. 77(4_Supplement). P3–4.

10.

Korpal, Manav, Jacob Feala, Xiaoling Puyang, et al.. (2015). Implementation of <em>In Vitro</em> Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms. Journal of Visualized Experiments. e52879–e52879. 2 indexed citations

11.

Mounir, Zineb, Fallon Lin, Joshua M. Korn, et al.. (2014). TMPRSS2:ERG blocks neuroendocrine and luminal cell differentiation to maintain prostate cancer proliferation. Oncogene. 34(29). 3815–3825. 46 indexed citations

12.

Korpal, Manav, Joshua M. Korn, Xueliang Gao, et al.. (2013). An F876L Mutation in Androgen Receptor Confers Genetic and Phenotypic Resistance to MDV3100 (Enzalutamide). Cancer Discovery. 3(9). 1030–1043. 425 indexed citations breakdown →

13.

Grassian, Alexandra, Fallon Lin, Rosemary Barrett, et al.. (2012). Isocitrate Dehydrogenase (IDH) Mutations Promote a Reversible ZEB1/MicroRNA (miR)-200-dependent Epithelial-Mesenchymal Transition (EMT). Journal of Biological Chemistry. 287(50). 42180–42194. 83 indexed citations

14.

Korpal, Manav, Brian Ell, Francesca M. Buffa, et al.. (2011). Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization. Nature Medicine. 17(9). 1101–1108. 508 indexed citations breakdown →

15.

Korpal, Manav & Yibin Kang. (2010). Targeting the transforming growth factor-β signalling pathway in metastatic cancer. European Journal of Cancer. 46(7). 1232–1240. 72 indexed citations

16.

Korpal, Manav, et al.. (2009). Imaging transforming growth factor-β signaling dynamics and therapeutic response in breast cancer bone metastasis. Nature Medicine. 15(8). 960–966. 178 indexed citations

17.

Korpal, Manav, et al.. (2008). The miR-200 Family Inhibits Epithelial-Mesenchymal Transition and Cancer Cell Migration by Direct Targeting of E-cadherin Transcriptional Repressors ZEB1 and ZEB2. Journal of Biological Chemistry. 283(22). 14910–14914. 1353 indexed citations breakdown →

18.

Schulze, Harald, Marei Dose, Manav Korpal, et al.. (2008). RanBP10 Is a Cytoplasmic Guanine Nucleotide Exchange Factor That Modulates Noncentrosomal Microtubules. Journal of Biological Chemistry. 283(20). 14109–14119. 46 indexed citations

19.

Korpal, Manav & Yibin Kang. (2008). The emerging role of miR-200 family of MicroRNAs in epithelial-mesenchymal transition and cancer metastasis. RNA Biology. 5(3). 115–119. 315 indexed citations

20.

Schulze, Harald, Manav Korpal, Jonathan Hurov, et al.. (2006). Characterization of the megakaryocyte demarcation membrane system and its role in thrombopoiesis. Blood. 107(10). 3868–3875. 139 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact